The North America In-Vitro Diagnostics Market: 2030 Outlook

Name: The North America In-Vitro Diagnostics Market: 2030 Outlook
Creator: Next Move Strategy Consulting
Published: 2025-08-14T20:00:00-04:00
License: https://www.nextmsc.com/privacy-policy

About Report

Download Now

North America In-Vitro Diagnostic Market By Product & Service (Reagents & Consumables, Instruments & Devices, and Software & Services), By Technique (Clinical Chemistry, Immunoassays, Molecular Diagnostics, and Others), By Testing Site/Channel (Central & Reference Laboratories, Hospital & Physician Labs, Point-of-Care & Retail, and Others), By Application (Infectious Diseases, Oncology, Cardiovascular Health, and Others) – Opportunity Analysis and Industry Forecast, 2024–2030.

Download PDF

Speak to Our Analyst

Market Overview

The North America In-Vitro Diagnostics Market size was valued at USD 33.54 billion in 2023, and is predicted to reach USD 43.64 billion by 2030, at a CAGR of 3.4% from 2024 to 2030. In-vitro diagnostics (IVD) refers to a wide range of medical tests conducted on samples of bodily fluids, tissues, or cells outside of the body to diagnose diseases, monitor therapy, and assess overall health conditions. These tests are performed in laboratory settings using various techniques and technologies, including immunoassays, molecular diagnostics, clinical chemistry, hematology, and microbiology.

IVD tests enable early detection of diseases, allowing for timely intervention and treatment initiation. By providing rapid and accurate results, these tests facilitate personalized medicine, guiding tailored treatment approaches based on individual patient characteristics. Also, immunoassay experiments provide valuable insights into biological systems, enabling scientists and researchers to make significant contributions to fields such as medicine, biotechnology, and pharmacology. They serve as essential tools for understanding fundamental biological processes and developing innovative solutions to address health challenges.

Rising Rates of Chronic and Infectious Diseases are Significantly Boosting the Market Growth in North America

The increasing prevalence of chronic and infectious diseases such as cancer, cardiovascular conditions, diabetes, and various infections is driving the demand for diagnostic tests in the global in-vitro diagnostics market. As healthcare systems work to tackle these rising health challenges, there is a stronger focus on early detection, disease monitoring, and personalized treatment strategies.

According to the World Health Organization, Noncommunicable Diseases (NCDs) account for a staggering 41 million deaths annually, representing around 74% of all global fatalities. Cardiovascular diseases are the leading cause, resulting in 17.9 million deaths each year, followed by cancers at 9.3 million, chronic respiratory diseases at 4.1 million, and diabetes at 2 million.

In-vitro diagnostics, with their ability to provide rapid and accurate diagnostic information, are indispensable in facilitating proactive healthcare interventions and improving patient outcomes. Consequently, the North America in-vitro diagnostics market is poised for substantial expansion as healthcare systems worldwide intensify efforts to combat the burgeoning burden of chronic and infectious diseases.

The Growing Aging Population Drives the Expansion of the In-Vitro Diagnostics Market in North America

The aging population, marked by a rising prevalence of age-related diseases and conditions worldwide, is a key driver for the growth of the market in the region. As people age, the incidence of these conditions increases, leading to a higher demand for diagnostic tests for early detection, monitoring, and management to prevent further progression and complications.

This demographic shift is clearly observable from the projected rise of individuals aged 65 years and older, expected to more than double from 761 million in 2021 to 1.6 billion by 2050 worldwide. As a result, healthcare providers are confronted with the increasing task of meeting the changing healthcare requirements of elderly individuals, driving the need for advanced diagnostic solutions.

Moreover, the specific healthcare demands of the aging population emphasize the necessity for precise diagnostic technologies tailored to individual needs. Therefore, the aging demographic plays a pivotal role in shaping the North America in-vitro diagnostics market demand and development, influencing its future trajectory.

High Research, Development, and Regulatory Approval Costs Hinder the IVD Market Growth in North America

High costs associated with research, development, and regulatory approval are significant factors restraining the market growth in North America. Operating within this sector necessitates significant financial investment for companies to navigate the complex landscape of research and development.

This investment often encompasses extensive clinical trials, laboratory testing, and product refinement to guarantee accuracy and reliability. Additionally, obtaining regulatory approvals from agencies such as the FDA requires strict adherence to stringent standards, further compounding the financial burden. This financial constraint can discourage potential adopters from market expansion.

Introduction of Point-of-Care Testing Solutions in IVD Creates Opportunity

Point-of-care testing (POCT) is poised to be a significant driver of growth in the North America IVD market in the forthcoming years. POCT serves as a valuable complement to laboratory testing, especially in situations where immediate results are crucial, such as emergency departments, ambulances, and remote healthcare settings.

With POCT technologies offering rapid tests for infectious diseases, cardiac markers, glucose monitoring, pregnancy testing, and more, healthcare providers can quickly assess patients' conditions and make timely treatment decisions.

By integrating POCT with traditional IVD, healthcare providers can enhance their diagnostic capabilities, delivering more efficient and patient-centered care. This integration streamlines workflows, allowing for faster diagnosis and treatment initiation, ultimately leading to improved patient outcomes.

U.S. Dominates the North America In-Vitro Diagnostics Market Share

The prevalence of chronic diseases serves as a significant growth driver for the IVD market in the U.S. Chronic conditions such as diabetes, cardiovascular diseases, and cancer are increasingly common among the population, leading to a heightened demand for diagnostic tests.

Early detection and ongoing monitoring of these diseases are crucial for effective management and treatment. The National association of Chronic Disease Directors reported that cardiovascular diseases accounts for one out of every three deaths in the U.S., totalling 859,000 deaths every year.

In response to this, the demand for molecular testings are rising, facilitating diagnosis, monitoring, and management of chronic diseases in this region. Through innovative technologies and advancements in diagnostic techniques, healthcare providers can better identify individuals at risk, tailor treatment plans to individual needs, and improve patient outcomes.

Canada to Witness Substantial Growth in the Market

Expansion in healthcare expenditure is significantly driving the in-vitro diagnostics industry growth in this region. The Canadian medical Association reported that, Canada allocates about USD 220 billion annually towards healthcare expenditure.

As healthcare expenditure increases, there is a greater allocation of resources towards improving healthcare infrastructure, enhancing medical facilities, and expanding access to healthcare services, including diagnostic testing. This includes the adoption of innovative products and platforms that offer more accurate, efficient, and timely diagnostic. These investments enable healthcare facilities to enhance their diagnostic capabilities, improve patient care, and achieve better treatment outcomes.

Competitive Landscape

The promising players operating in the North America in-vitro diagnostics market include Roche Holding AG, Abbott Laboratories, Thermo Fisher Scientific Inc, Danaher Corporation, Becton, Dickinson and Company, Siemens Healthineers AG, bioMérieux SA, Sysmex Corporation, QIAGEN N.V., and Bio-Rad Laboratories, Inc., and others.

North America In-Vitro Diagnostics Market Key Segments

By Product & Service

Reagents & Consumables
- Clinical Chemistry Reagents
- Immunoassay Reagents (ELISA/CLIA)
- Molecular Master Mixes
- Hematology Controls
Instruments & Devices
- Chemistry Analyzers
- Immunoassay Systems
- Molecular Thermocyclers/Sequencers
- Hematology Analyzers
- POC Devices
Software & Services
- LIS, Data Analytics
- CRO/Testing Services

By Technique

Clinical Chemistry
- Metabolites
- Electrolytes
- Enzymes
Immunoassays
- ELISA / CLIA / CMIA
- Lateral-flow Rapid Tests
- Immunofluorescence
Molecular Diagnostics
- PCR
- Isothermal NAAT
- NGS
- In-situ Hybridization
Hematology & Coagulation
- CBC Analyzers
- Coagulation Panels
Microbiology
- Culture & Sensitivity
- MALDI-TOF
- Molecular ID
Urinalysis & Body Fluids
Other Techniques

By Testing Site / Channel

Central & Reference Laboratories
Hospital & Physician Labs
Point-of-Care & Retail
Home & Self-Testing

By Application

Infectious Diseases
Oncology
Cardiovascular Health
Endocrinology & Diabetes
Nephrology
Genetic & Prenatal Testing
Autoimmune Disorders
Drug Monitoring & Toxicology
Blood Screening & Typing
Other Indications

By Country

U.S
Canada
Mexico

KEY PLAYERS

Roche Holding AG
Abbott Laboratories
Thermo Fisher Scientific Inc.
Danaher Corporation
Becton, Dickinson and Company
Siemens Healthineers AG
bioMérieux SA
Sysmex Corporation
QIAGEN N.V.
Bio-Rad Laboratories, Inc.

Report Scope and Segmentation

Parameters	Details
Market Size Value in 2023	USD 33.54 billion
Revenue Forecast in 2030	USD 43.64 billion
Value Growth Rate	CAGR of 3.4% from 2024 to 2030
Analysis Period	2023–2030
Base Year Considered	2023
Forecast Period	2024–2030
Market Size Estimation	Billion (USD)
Growth Factors	Rising Rates of Chronic and Infectious Diseases are Significantly Boosting the Market Growth. The Growing Aging Population Drives the Expansion of the In-Vitro Diagnostics Market.
Companies Profiled	10
Countries Covered	3
Customization Scope	Free customization (equivalent up to 80 working hours of analysts) after purchase. Addition or alteration to country, regional, and segment scope.
Pricing and Purchase Options	Avail customized purchase options to meet your exact research needs.

About the Author

Sikha Haritwal is an assistant manager with strong expertise in market research, data analysis, and cross-functional coordination. She plays a key role in leading complex research initiatives, strengthening analytical rigor, and enabling data-driven decision-making across teams. Known for her leadership mindset and structured problem-solving approach, she supports process improvement, enhances operational efficiency, and contributes to building scalable frameworks that drive long-term strategic outcomes and organizational effectiveness.

About the Reviewer

Supradip Baul is an accomplished business consultant and strategist with over a decade of rich experience in market intelligence, strategy, technology, and business transformation. His work has included rigorous qualitative and quantitative analysis across multiple industries, helping clients shape investment decisions and long-term roadmaps. Earlier in his career, he was associated with Gartner, where he contributed to industry-leading reports and market share analyses. He has worked with leading global companies and holds an MBA with a dual specialization in Marketing and Finance.

1. 1.1 REPORT DESCRIPTION
2. 1.2 RESEARCH METHODOLOGY
3. 1. 1.2.1 SECONDARY RESEARCH
  2. 1.2.2 DATA ANALYSIS FRAMEWORK
  3. 1.2.3 MARKET SIZE ESTIMATION
  4. 1.2.4 FORECASTING
  5. 1.2.5 PRIMARY RESEARCH AND DATA VALIDATION

1. 2.1. MARKET SNAPSHOT, 2023 - 2030, MILLION USD

1. 3.1 BARGAINING POWER OF SUPPLIERS
2. 3.2 BARGAINING POWER OF BUYERS
3. 3.3 DEGREE OF COMPETITION
4. 3.4 THREAT OF SUBSTITUTE
5. 3.5 THREAT OF NEW ENTRANTS

1. 4.1 MARKET SHARE ANALYSIS OF TOP PROVIDERS, 2023

1. 5.1 GROWTH DRIVERS
2. 1. 5.1.1 DRIVER 1
  2. 5.1.2 DRIVER 2
  3. 5.1.3 DRIVER 3
  4. 5.1.4 DRIVER 4
3. 5.2 CHALLENGES
4. 1. 5.2.1 CHALLENGE 1
  2. 5.2.2 CHALLENGE 2
  3. 5.2.3 CHALLENGE 3
  4. 5.2.4 CHALLENGE 4
5. 5.3 OPPORTUNITIES
6. 1. 5.3.1 OPPORTUNITY 1
  2. 5.3.2 OPPORTUNITY 2

1. 6.1 OVERVIEW
2. 6.2 REAGENTS
3. 1. 6.2.1 REAGENTS MARKET, BY COUNTRY
4. 6.3 INSTRUMENTS
5. 1. 6.3.1 INSTRUMENTS MARKET, BY COUNTRY
6. 6.4 SOFTWARE AND SERVICES
7. 1. 6.4.1 SOFTWARE AND SERVICES MARKET, BY COUNTRY

1. 7.1 OVERVIEW
2. 7.2 IMMUNODIAGNOSTICS
3. 1. 7.2.1 IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE
  2. 1. 7.2.1.1 ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) MARKET, BY COUNTRY
    2. 7.2.1.2 RAPID TESTS MARKET, BY COUNTRY
    3. 7.2.1.3 CHEMILUMINESCENCE IMMUNOASSAY (CLIA) MARKET, BY COUNTRY
    4. 7.2.1.4 ENZYME-LINKED IMMUNOSORBENT SPOT (ELISPOT) MARKET, BY COUNTRY
    5. 7.2.1.5 RADIOIMMUNOASSAY (RIA) MARKET, BY COUNTRY
    6. 7.2.1.6 WESTERN BLOT MARKET, BY COUNTRY
  3. 7.2.2 IMMUNODIAGNOSTICS MARKET, BY COUNTRY
4. 7.3 HEMATOLOGY
5. 1. 7.3.1 HEMATOLOGY MARKET, BY COUNTRY
6. 7.4 MOLECULAR DIAGNOSTICS
7. 1. 7.4.1 MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE
  2. 1. 7.4.1.1 PCR MARKET, BY COUNTRY
    2. 7.4.1.2 INAAT MARKET, BY COUNTRY
    3. 7.4.1.3 HYBRIDIZATION MARKET, BY COUNTRY
    4. 7.4.1.4 DNA DIAGNOSTICS MARKET, BY COUNTRY
    5. 7.4.1.5 MICROARRAY MARKET, BY COUNTRY
    6. 7.4.1.6 OTHER MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY
  3. 7.4.2 MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY
8. 7.5 TISSUE DIAGNOSTICS
9. 1. 7.5.1 TISSUE DIAGNOSTICS MARKET, BY COUNTRY
10. 7.6 CLINICAL CHEMISTRY
11. 1. 7.6.1 CLINICAL CHEMISTRY MARKET, BY TECHNIQUE
  2. 1. 7.6.1.1 BASIC METABOLIC PANEL MARKET, BY COUNTRY
    2. 7.6.1.2 LIVER PANEL MARKET, BY COUNTRY
    3. 7.6.1.3 RENAL PROFILE MARKET, BY COUNTRY
    4. 7.6.1.4 LIPID PROFILE MARKET, BY COUNTRY
    5. 7.6.1.5 THYROID FUNCTION PANEL MARKET, BY COUNTRY
    6. 7.6.1.6 ELECTROLYTE PANEL MARKET, BY COUNTRY
    7. 7.6.1.7 SPECIALITY CHEMICALS MARKET, BY COUNTRY
  3. 7.6.2 CLINICAL CHEMISTRY MARKET, BY COUNTRY
12. 7.7 OTHER IVD TECHNIQUES
13. 1. 7.7.1 OTHER IVD TECHNIQUES MARKET, BY COUNTRY

1. 8.1 OVERVIEW
2. 8.2 INFECTIOUS DISEASES
3. 1. 8.2.1 INFECTIOUS DISEASES MARKET, BY COUNTRY
4. 8.3 CANCER
5. 1. 8.3.1 CANCER MARKET, BY COUNTRY
6. 8.4 CARDIAC DISEASES
7. 1. 8.4.1 CARDIAC DISEASES MARKET, BY COUNTRY
8. 8.5 IMMUNE SYSTEM DISORDERS
9. 1. 8.5.1 IMMUNE SYSTEM DISORDERS MARKET, BY COUNTRY
10. 8.6 NEPHROLOGICAL DISEASES
11. 1. 8.6.1 NEPHROLOGICAL DISEASES MARKET, BY COUNTRY
12. 8.7 GASTROINTESTINAL DISEASES
13. 1. 8.7.1 GASTROINTESTINAL DISEASES MARKET, BY COUNTRY
14. 8.8 OTHERS
15. 1. 8.8.1 OTHERS MARKET, BY COUNTRY

1. 9.1 OVERVIEW
2. 9.2 STAND ALONE LABORATORY
3. 1. 9.2.1 STAND ALONE LABORATORY MARKET, BY COUNTRY
4. 9.3 HOSPITALS
5. 1. 9.3.1 HOSPITALS MARKET, BY COUNTRY
6. 9.4 ACADEMICS AND MEDICAL SCHOOLS
7. 1. 9.4.1 ACADEMICS AND MEDICAL SCHOOLS MARKET, BY COUNTRY
8. 9.5 POINT OF CARE TESTING
9. 1. 9.5.1 POINT OF CARE TESTING MARKET, BY COUNTRY
10. 9.6 OTHER END USERS
11. 1. 9.6.1 OTHER END USERS MARKET, BY COUNTRY

1. 10.1 OVERVIEW
2. 10.2 UNITED STATES
3. 1. 10.2.1 NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET, BY TYPE
  2. 10.2.2 NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE
  3. 10.2.3 NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION
  4. 10.2.4 NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET, BY END USER
4. 10.3 CANADA
5. 1. 10.3.1 NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET, BY TYPE
  2. 10.3.2 NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE
  3. 10.3.3 NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION
  4. 10.3.4 NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET, BY END USER
6. 10.4 MEXICO
7. 1. 10.4.1 NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET, BY TYPE
  2. 10.4.2 NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE
  3. 10.4.3 NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION
  4. 10.4.4 NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET, BY END USER

1. 11.1 ROCHE HOLDING AG
2. 1. 11.1.1 COMPANY OVERVIEW
  2. 11.1.2 COMPANY SNAPSHOT
  3. 11.1.3 OPERATING BUSINESS SEGMENTS
  4. 11.1.4 PRODUCT PORTFOLIO
  5. 11.1.5 BUSINESS PERFORMANCE
  6. 11.1.6 BUSINESS SEGMENTS
  7. 11.1.7 GEOGRAPHIC SEGMENTS
  8. 11.1.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 11.1.9 PRIMARY MARKET COMPETITORS
3. 11.2 ABBOTT LABORATORIES
4. 1. 11.2.1 COMPANY OVERVIEW
  2. 11.2.2 COMPANY SNAPSHOT
  3. 11.2.3 OPERATING BUSINESS SEGMENTS
  4. 11.2.4 PRODUCT PORTFOLIO
  5. 11.2.5 BUSINESS PERFORMANCE
  6. 11.2.6 BUSINESS SEGMENTS
  7. 11.2.7 GEOGRAPHIC SEGMENTS
  8. 11.2.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 11.2.9 PRIMARY MARKET COMPETITORS
5. 11.3 THERMO FISHER SCIENTIFIC INC.
6. 1. 11.3.1 COMPANY OVERVIEW
  2. 11.3.2 COMPANY SNAPSHOT
  3. 11.3.3 OPERATING BUSINESS SEGMENTS
  4. 11.3.4 PRODUCT PORTFOLIO
  5. 11.3.5 BUSINESS PERFORMANCE
  6. 11.3.6 BUSINESS SEGMENTS
  7. 11.3.7 GEOGRAPHIC SEGMENTS
  8. 11.3.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 11.3.9 PRIMARY MARKET COMPETITORS
7. 11.4 DANAHER CORPORATION
8. 1. 11.4.1 COMPANY OVERVIEW
  2. 11.4.2 COMPANY SNAPSHOT
  3. 11.4.3 OPERATING BUSINESS SEGMENTS
  4. 11.4.4 PRODUCT PORTFOLIO
  5. 11.4.5 BUSINESS PERFORMANCE
  6. 11.4.6 BUSINESS SEGMENTS
  7. 11.4.7 GEOGRAPHIC SEGMENTS
  8. 11.4.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 11.4.9 PRIMARY MARKET COMPETITORS
9. 11.5 BECTON, DICKINSON AND COMPANY
10. 1. 11.5.1 COMPANY OVERVIEW
  2. 11.5.2 COMPANY SNAPSHOT
  3. 11.5.3 OPERATING BUSINESS SEGMENTS
  4. 11.5.4 PRODUCT PORTFOLIO
  5. 11.5.5 BUSINESS PERFORMANCE
  6. 11.5.6 BUSINESS SEGMENTS
  7. 11.5.7 GEOGRAPHIC SEGMENTS
  8. 11.5.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 11.5.9 PRIMARY MARKET COMPETITORS
11. 11.6 SIEMENS HEALTHINEERS AG
12. 1. 11.6.1 COMPANY OVERVIEW
  2. 11.6.2 COMPANY SNAPSHOT
  3. 11.6.3 OPERATING BUSINESS SEGMENTS
  4. 11.6.4 PRODUCT PORTFOLIO
  5. 11.6.5 BUSINESS PERFORMANCE
  6. 11.6.6 BUSINESS SEGMENTS
  7. 11.6.7 GEOGRAPHIC SEGMENTS
  8. 11.6.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 11.6.9 PRIMARY MARKET COMPETITORS
13. 11.7 BIOMÉRIEUX SA
14. 1. 11.7.1 COMPANY OVERVIEW
  2. 11.7.2 COMPANY SNAPSHOT
  3. 11.7.3 OPERATING BUSINESS SEGMENTS
  4. 11.7.4 PRODUCT PORTFOLIO
  5. 11.7.5 BUSINESS PERFORMANCE
  6. 11.7.6 BUSINESS SEGMENTS
  7. 11.7.7 GEOGRAPHIC SEGMENTS
  8. 11.7.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 11.7.9 PRIMARY MARKET COMPETITORS
15. 11.8 SYSMEX CORPORATION
16. 1. 11.8.1 COMPANY OVERVIEW
  2. 11.8.2 COMPANY SNAPSHOT
  3. 11.8.3 OPERATING BUSINESS SEGMENTS
  4. 11.8.4 PRODUCT PORTFOLIO
  5. 11.8.5 BUSINESS PERFORMANCE
  6. 11.8.6 BUSINESS SEGMENTS
  7. 11.8.7 GEOGRAPHIC SEGMENTS
  8. 11.8.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 11.8.9 PRIMARY MARKET COMPETITORS
17. 11.9 QIAGEN N.V.
18. 1. 11.9.1 COMPANY OVERVIEW
  2. 11.9.2 COMPANY SNAPSHOT
  3. 11.9.3 OPERATING BUSINESS SEGMENTS
  4. 11.9.4 PRODUCT PORTFOLIO
  5. 11.9.5 BUSINESS PERFORMANCE
  6. 11.9.6 BUSINESS SEGMENTS
  7. 11.9.7 GEOGRAPHIC SEGMENTS
  8. 11.9.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 11.9.9 PRIMARY MARKET COMPETITORS
19. 11.10 BIO-RAD LABORATORIES, INC.
20. 1. 11.10.1 COMPANY OVERVIEW
  2. 11.10.2 COMPANY SNAPSHOT
  3. 11.10.3 OPERATING BUSINESS SEGMENTS
  4. 11.10.4 PRODUCT PORTFOLIO
  5. 11.10.5 BUSINESS PERFORMANCE
  6. 11.10.6 BUSINESS SEGMENTS
  7. 11.10.7 GEOGRAPHIC SEGMENTS
  8. 11.10.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 11.10.9 PRIMARY MARKET COMPETITORS

TABLE 1. NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET VALUE, BY TYPE, 2023-2030, (MILLION USD)
TABLE 2. REAGENTS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
TABLE 3. INSTRUMENTS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
TABLE 4. SOFTWARE AND SERVICES, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
TABLE 5. NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE, 2023-2030, (MILLION USD)
TABLE 6. ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA), MARKET VALUE, BY COUNTRY 2023-2030, (MILLION USD)
TABLE 7. RAPID TESTS, MARKET VALUE, BY COUNTRY 2023-2030, (MILLION USD)
TABLE 8. CHEMILUMINESCENCE IMMUNOASSAY (CLIA), MARKET VALUE, BY COUNTRY 2023-2030, (MILLION USD)
TABLE 9. ENZYME-LINKED IMMUNOSORBENT SPOT (ELISPOT), MARKET VALUE, BY COUNTRY 2023-2030, (MILLION USD)
TABLE 10. RADIOIMMUNOASSAY (RIA), MARKET VALUE, BY COUNTRY 2023-2030, (MILLION USD)
TABLE 11. WESTERN BLOT, MARKET VALUE, BY COUNTRY 2023-2030, (MILLION USD)
TABLE 12. IMMUNODIAGNOSTICS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
TABLE 13. HEMATOLOGY, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
TABLE 14. PCR, MARKET VALUE, BY COUNTRY 2023-2030, (MILLION USD)
TABLE 15. INAAT, MARKET VALUE, BY COUNTRY 2023-2030, (MILLION USD)
TABLE 16. HYBRIDIZATION, MARKET VALUE, BY COUNTRY 2023-2030, (MILLION USD)
TABLE 17. DNA DIAGNOSTICS, MARKET VALUE, BY COUNTRY 2023-2030, (MILLION USD)
TABLE 18. MICROARRAY, MARKET VALUE, BY COUNTRY 2023-2030, (MILLION USD)
TABLE 19. OTHER MOLECULAR DIAGNOSTICS, MARKET VALUE, BY COUNTRY 2023-2030, (MILLION USD)
TABLE 20. MOLECULAR DIAGNOSTICS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
TABLE 21. TISSUE DIAGNOSTICS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
TABLE 22. BASIC METABOLIC PANEL, MARKET VALUE, BY COUNTRY 2023-2030, (MILLION USD)
TABLE 23. LIVER PANEL, MARKET VALUE, BY COUNTRY 2023-2030, (MILLION USD)
TABLE 24. RENAL PROFILE, MARKET VALUE, BY COUNTRY 2023-2030, (MILLION USD)
TABLE 25. LIPID PROFILE, MARKET VALUE, BY COUNTRY 2023-2030, (MILLION USD)
TABLE 26. THYROID FUNCTION PANEL, MARKET VALUE, BY COUNTRY 2023-2030, (MILLION USD)
TABLE 27. ELECTROLYTE PANEL, MARKET VALUE, BY COUNTRY 2023-2030, (MILLION USD)
TABLE 28. SPECIALITY CHEMICALS, MARKET VALUE, BY COUNTRY 2023-2030, (MILLION USD)
TABLE 29. CLINICAL CHEMISTRY, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
TABLE 30. OTHER IVD TECHNIQUES, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
TABLE 31. NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2023-2030, (MILLION USD)
TABLE 32. INFECTIOUS DISEASES, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
TABLE 33. CANCER, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
TABLE 34. CARDIAC DISEASES, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
TABLE 35. IMMUNE SYSTEM DISORDERS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
TABLE 36. NEPHROLOGICAL DISEASES, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
TABLE 37. GASTROINTESTINAL DISEASES, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
TABLE 38. OTHERS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
TABLE 39. NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET VALUE, BY END USER, 2023-2030, (MILLION USD)
TABLE 40. STAND ALONE LABORATORY, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
TABLE 41. HOSPITALS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
TABLE 42. ACADEMICS AND MEDICAL SCHOOLS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
TABLE 43. POINT OF CARE TESTING, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
TABLE 44. OTHER END USERS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
TABLE 45. NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
TABLE 46. UNITED STATES NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET VALUE, BY TYPE, 2023-2030, (MILLION USD)
TABLE 47. UNITED STATES NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE, 2023-2030, (MILLION USD)
TABLE 48. UNITED STATES NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2023-2030, (MILLION USD)
TABLE 49. UNITED STATES NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET VALUE, BY END USER, 2023-2030, (MILLION USD)
TABLE 50. CANADA NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET VALUE, BY TYPE, 2023-2030, (MILLION USD)
TABLE 51. CANADA NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE, 2023-2030, (MILLION USD)
TABLE 52. CANADA NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2023-2030, (MILLION USD)
TABLE 53. CANADA NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET VALUE, BY END USER, 2023-2030, (MILLION USD)
TABLE 54. MEXICO NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET VALUE, BY TYPE, 2023-2030, (MILLION USD)
TABLE 55. MEXICO NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE, 2023-2030, (MILLION USD)
TABLE 56. MEXICO NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2023-2030, (MILLION USD)
TABLE 57. MEXICO NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET VALUE, BY END USER, 2023-2030, (MILLION USD)
TABLE 58. ROCHE HOLDING AG: COMPANY SNAPSHOT
TABLE 59. ROCHE HOLDING AG: OPERATING BUSINESS SEGMENTS
TABLE 60. ROCHE HOLDING AG: PRODUCT PORTFOLIO
TABLE 61. ROCHE HOLDING AG: SALES BY BUSINESS SEGMENTS (2021-2023)
TABLE 62. ROCHE HOLDING AG: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)
TABLE 63. ROCHE HOLDING AG: KEY STRATERGY
TABLE 64. ABBOTT LABORATORIES: COMPANY SNAPSHOT
TABLE 65. ABBOTT LABORATORIES: OPERATING BUSINESS SEGMENTS
TABLE 66. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
TABLE 67. ABBOTT LABORATORIES: SALES BY BUSINESS SEGMENTS (2021-2023)
TABLE 68. ABBOTT LABORATORIES: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)
TABLE 69. ABBOTT LABORATORIES: KEY STRATERGY
TABLE 70. THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT
TABLE 71. THERMO FISHER SCIENTIFIC INC.: OPERATING BUSINESS SEGMENTS
TABLE 72. THERMO FISHER SCIENTIFIC INC.: PRODUCT PORTFOLIO
TABLE 73. THERMO FISHER SCIENTIFIC INC.: SALES BY BUSINESS SEGMENTS (2021-2023)
TABLE 74. THERMO FISHER SCIENTIFIC INC.: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)
TABLE 75. THERMO FISHER SCIENTIFIC INC.: KEY STRATERGY
TABLE 76. DANAHER CORPORATION: COMPANY SNAPSHOT
TABLE 77. DANAHER CORPORATION: OPERATING BUSINESS SEGMENTS
TABLE 78. DANAHER CORPORATION: PRODUCT PORTFOLIO
TABLE 79. DANAHER CORPORATION: SALES BY BUSINESS SEGMENTS (2021-2023)
TABLE 80. DANAHER CORPORATION: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)
TABLE 81. DANAHER CORPORATION: KEY STRATERGY
TABLE 82. BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT
TABLE 83. BECTON, DICKINSON AND COMPANY: OPERATING BUSINESS SEGMENTS
TABLE 84. BECTON, DICKINSON AND COMPANY: PRODUCT PORTFOLIO
TABLE 85. BECTON, DICKINSON AND COMPANY: SALES BY BUSINESS SEGMENTS (2021-2023)
TABLE 86. BECTON, DICKINSON AND COMPANY: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)
TABLE 87. BECTON, DICKINSON AND COMPANY: KEY STRATERGY
TABLE 88. SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT
TABLE 89. SIEMENS HEALTHINEERS AG: OPERATING BUSINESS SEGMENTS
TABLE 90. SIEMENS HEALTHINEERS AG: PRODUCT PORTFOLIO
TABLE 91. SIEMENS HEALTHINEERS AG: SALES BY BUSINESS SEGMENTS (2021-2023)
TABLE 92. SIEMENS HEALTHINEERS AG: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)
TABLE 93. SIEMENS HEALTHINEERS AG: KEY STRATERGY
TABLE 94. BIOMéRIEUX SA: COMPANY SNAPSHOT
TABLE 95. BIOMéRIEUX SA: OPERATING BUSINESS SEGMENTS
TABLE 96. BIOMéRIEUX SA: PRODUCT PORTFOLIO
TABLE 97. BIOMéRIEUX SA: SALES BY BUSINESS SEGMENTS (2021-2023)
TABLE 98. BIOMéRIEUX SA: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)
TABLE 99. BIOMéRIEUX SA: KEY STRATERGY
TABLE 100. SYSMEX CORPORATION: COMPANY SNAPSHOT
TABLE 101. SYSMEX CORPORATION: OPERATING BUSINESS SEGMENTS
TABLE 102. SYSMEX CORPORATION: PRODUCT PORTFOLIO
TABLE 103. SYSMEX CORPORATION: SALES BY BUSINESS SEGMENTS (2021-2023)
TABLE 104. SYSMEX CORPORATION: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)
TABLE 105. SYSMEX CORPORATION: KEY STRATERGY
TABLE 106. QIAGEN N.V.: COMPANY SNAPSHOT
TABLE 107. QIAGEN N.V.: OPERATING BUSINESS SEGMENTS
TABLE 108. QIAGEN N.V.: PRODUCT PORTFOLIO
TABLE 109. QIAGEN N.V.: SALES BY BUSINESS SEGMENTS (2021-2023)
TABLE 110. QIAGEN N.V.: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)
TABLE 111. QIAGEN N.V.: KEY STRATERGY
TABLE 112. BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT
TABLE 113. BIO-RAD LABORATORIES, INC.: OPERATING BUSINESS SEGMENTS
TABLE 114. BIO-RAD LABORATORIES, INC.: PRODUCT PORTFOLIO
TABLE 115. BIO-RAD LABORATORIES, INC.: SALES BY BUSINESS SEGMENTS (2021-2023)
TABLE 116. BIO-RAD LABORATORIES, INC.: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)
TABLE 117. BIO-RAD LABORATORIES, INC.: KEY STRATERGY

FIGURE 1. BARGAINING POWER OF SUPPLIERS
FIGURE 2. BARGAINING POWER OF BUYERS
FIGURE 3. DEGREE OF COMPETITION
FIGURE 4. THREAT OF SUBSTITUTE
FIGURE 5. THREAT OF NEW ENTRANTS
FIGURE 6. NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET VALUE, BY TYPE, 2023-2030, (MILLION USD)
FIGURE 7. REAGENTS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 8. INSTRUMENTS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 9. SOFTWARE AND SERVICES, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 10. NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE, 2023-2030, (MILLION USD)
FIGURE 11. ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA), MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 12. RAPID TESTS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 13. CHEMILUMINESCENCE IMMUNOASSAY (CLIA), MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 14. ENZYME-LINKED IMMUNOSORBENT SPOT (ELISPOT), MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 15. RADIOIMMUNOASSAY (RIA), MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 16. WESTERN BLOT, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 17. IMMUNODIAGNOSTICS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 18. HEMATOLOGY, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 19. PCR, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 20. INAAT, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 21. HYBRIDIZATION, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 22. DNA DIAGNOSTICS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 23. MICROARRAY, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 24. OTHER MOLECULAR DIAGNOSTICS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 25. MOLECULAR DIAGNOSTICS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 26. TISSUE DIAGNOSTICS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 27. BASIC METABOLIC PANEL, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 28. LIVER PANEL, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 29. RENAL PROFILE, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 30. LIPID PROFILE, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 31. THYROID FUNCTION PANEL, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 32. ELECTROLYTE PANEL, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 33. SPECIALITY CHEMICALS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 34. CLINICAL CHEMISTRY, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 35. OTHER IVD TECHNIQUES, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 36. NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2023-2030, (MILLION USD)
FIGURE 37. INFECTIOUS DISEASES, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 38. CANCER, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 39. CARDIAC DISEASES, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 40. IMMUNE SYSTEM DISORDERS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 41. NEPHROLOGICAL DISEASES, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 42. GASTROINTESTINAL DISEASES, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 43. OTHERS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 44. NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET VALUE, BY END USER, 2023-2030, (MILLION USD)
FIGURE 45. STAND ALONE LABORATORY, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 46. HOSPITALS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 47. ACADEMICS AND MEDICAL SCHOOLS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 48. POINT OF CARE TESTING, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 49. OTHER END USERS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 50. NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET VALUE, BY REGION 2023-2030, (MILLION USD)
FIGURE 51. UNITED STATES NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET VALUE, BY TYPE 2023-2030, (MILLION USD)
FIGURE 52. UNITED STATES NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE 2023-2030, (MILLION USD)
FIGURE 53. UNITED STATES NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION 2023-2030, (MILLION USD)
FIGURE 54. UNITED STATES NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET VALUE, BY END USER 2023-2030, (MILLION USD)
FIGURE 55. CANADA NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET VALUE, BY TYPE 2023-2030, (MILLION USD)
FIGURE 56. CANADA NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE 2023-2030, (MILLION USD)
FIGURE 57. CANADA NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION 2023-2030, (MILLION USD)
FIGURE 58. CANADA NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET VALUE, BY END USER 2023-2030, (MILLION USD)
FIGURE 59. MEXICO NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET VALUE, BY TYPE 2023-2030, (MILLION USD)
FIGURE 60. MEXICO NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE 2023-2030, (MILLION USD)
FIGURE 61. MEXICO NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION 2023-2030, (MILLION USD)
FIGURE 62. MEXICO NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET VALUE, BY END USER 2023-2030, (MILLION USD)
FIGURE 63. ROCHE HOLDING AG: NET SALES, (2021-2023)
FIGURE 64. ROCHE HOLDING AG: PRIMARY MARKET COMPETITORS
FIGURE 65. ABBOTT LABORATORIES: NET SALES, (2021-2023)
FIGURE 66. ABBOTT LABORATORIES: PRIMARY MARKET COMPETITORS
FIGURE 67. THERMO FISHER SCIENTIFIC INC.: NET SALES, (2021-2023)
FIGURE 68. THERMO FISHER SCIENTIFIC INC.: PRIMARY MARKET COMPETITORS
FIGURE 69. DANAHER CORPORATION: NET SALES, (2021-2023)
FIGURE 70. DANAHER CORPORATION: PRIMARY MARKET COMPETITORS
FIGURE 71. BECTON, DICKINSON AND COMPANY: NET SALES, (2021-2023)
FIGURE 72. BECTON, DICKINSON AND COMPANY: PRIMARY MARKET COMPETITORS
FIGURE 73. SIEMENS HEALTHINEERS AG: NET SALES, (2021-2023)
FIGURE 74. SIEMENS HEALTHINEERS AG: PRIMARY MARKET COMPETITORS
FIGURE 75. BIOMéRIEUX SA: NET SALES, (2021-2023)
FIGURE 76. BIOMéRIEUX SA: PRIMARY MARKET COMPETITORS
FIGURE 77. SYSMEX CORPORATION: NET SALES, (2021-2023)
FIGURE 78. SYSMEX CORPORATION: PRIMARY MARKET COMPETITORS
FIGURE 79. QIAGEN N.V.: NET SALES, (2021-2023)
FIGURE 80. QIAGEN N.V.: PRIMARY MARKET COMPETITORS
FIGURE 81. BIO-RAD LABORATORIES, INC.: NET SALES, (2021-2023)
FIGURE 82. BIO-RAD LABORATORIES, INC.: PRIMARY MARKET COMPETITORS

At Next Move Strategy Consulting, we understand that insightful market research is the cornerstone of successful business decisions. That's why we employ a robust and multifaceted approach, combining various methodologies to deliver the most accurate and actionable data for our clients.

Research Landscape

We navigate the world of research with two primary approaches:

Qualitative Approach

Our qualitative research methodologies involve immersive techniques such as in-depth interviews, focus groups, and observational studies. By engaging directly with individuals and stakeholders, we uncover valuable insights that quantitative data alone may overlook.

Quantitative Research

In tandem with qualitative methodologies, NMSC leverages the power of Quantitative Research to provide a robust foundation of numerical insights. Through systematic data collection and analysis, we quantify patterns, preferences, and market trends, offering a comprehensive view of the business landscape.

Our quantitative research approach employs diverse tools, including surveys, experiments, and statistical modelling. These methodologies enable us to gather data from a large and representative sample, ensuring the statistical significance of our findings. By employing structured questionnaires and standardized data collection methods, we guarantee the reliability and validity of the information we present to our clients.

Quantitative research is particularly effective in measuring the prevalence of trends, assessing market size, and gauging the impact of various factors on consumer behavior. The numerical precision attained through this approach equips our clients with actionable insights, facilitating data-driven decision-making and strategy formulation.

Our Specialized Toolbox for Industry-Specific Market Research

We deploy a specialized arsenal of techniques tailored to meet your unique requirements. Here's a glimpse into our comprehensive toolbox:

Information Procurement

The stage entails acquiring market data or relevant information through various sources and methodologies.

Market Research Approach

We utilize both top-down and bottom-up approaches in market research analysis to achieve a comprehensive understanding of the market dynamics, leveraging the broad perspective of industry trends and macroeconomic factors alongside detailed insights from specific segments and individual companies.

Porters Five Forces Analysis

We conduct Porter's Five Forces analysis to evaluate the competitive landscape of an industry, providing us with insights into factors that affect profitability and strategic positioning.

SWOT Analysis

Forecasting

We utilize a forecasting model to predict future consumption by considering parameters like population, economics, regulations, market competition, drivers, constraints, technology, and pricing. We also employ statistical techniques such as multilinear regression, exponential smoothing, moving average, ARIMA, and Monte Carlo simulations for accurate predictions. In econometric forecasting, we analyzed short-term and long-term event impacts, attributing values based on regulatory frameworks, economic factors, and market events.

Download Free Sample

Full Name *

Please Enter Full Name

Business Email Id *

Please Enter Valid Email ID

Phone Number *

Please enter Country Code and Phone No

Message

Please enter message

Yes, I have read the Privacy Policy

Frequently Asked Questions

The North America in-vitro diagnostics market size was valued at USD 33.54 billion in 2023 and is projected to grow at a CAGR of 3.4% to reach USD 43.64 billion by 2030.

The key market players operating in the North America in-vitro diagnostics industry include Roche Holding AG, Abbott Laboratories, Thermo Fisher Scientific Inc, Danaher Corporation, Becton, Dickinson and Company, Siemens Healthineers AG, bioMérieux SA, Sysmex Corporation, QIAGEN N.V., and Bio-Rad Laboratories, Inc., and others.

U.S. holds the largest share of the North America IVD market, owing to rising rates of chronic and infectious diseases.

High costs associated with research, development, and regulatory approval are significant factors restraining the North America in-vitro diagnostics market growth.

Introduction of Point-of-Care Testing Solutions creates opportunities for the North America in-vitro diagnostics market landscape, in the coming future.

Purchase Options Flash
sale

Multi User

$3,917 $5595

Single User

$3,217 $4595

Enterprise

$5,317 $7595

Datapack

$1,817 $2595

Download Sample

Inquire Before Buying